PHARMA SOLUTIONS

Smarter imaging solutions for faster clinical trials

Explore Our Focus Areas

Cardio Metabolic

Comprehensive imaging solutions to enrich obesity, metabolic, and neuromuscular disease clinical trials. Unravel the hidden benefits of such treatments through understanding patients’ body composition and multi-organ health using quantitative MRI and DXA.

Body composition metrics

Our body composition analysis measures changes in fat deposition and lean muscle at various anatomical locations in both 2D and 3D, allowing the tracking of changes in participant phenotypes, moving beyond ‘weight loss’ alone.

Skeletal muscle
Visceral adipose tissue (VAT)
Subcutaneous adipose tissue (SAT)
Suspected brown adipose tissue (sBAT)
Muscle Fat infiltration

Multi-organ imaging and ectopic fat deposition

Emerging obesity and MetD treatments – including GLP-1 RAs – have demonstrated robust improvements in multi-organ health. Capture these systemic improvements through our multi-organ imaging portfolio.

DXA

Understand body composition and bone health through a standardized and centralized reporting service, ensuring quality assurance and reliable data insights encapsulated within a configurable and customizable reporting structure.

Lean mass
Fat mass
Total mass
Percentage body fat
Bone mineral density T-scores

Renal imaging

Our renal imaging suite delivers an extensive assessment of structural and functional metrics that can be used to screen for eligible patients and assess therapeutic efficacy. We bring a rich knowledge base with dedicated experts and a proven track record of innovation in the space of renal imaging, with 30 years of industry experience and 100+ publications in peer-reviewed journals.

Cardiac imaging

Using our cardiac imaging services, comprehensive assessments of cardiac structure and function can be carried out in a sub 30 minute non-contrast scan – maximising patient comfort and scanner capacity.

Established imaging network

Our established imaging network has locations across the global, paired with our in-house developed central platform we can scale our services to meet the most comprehensive and complex clinical trial requirements.

Back to focus areas

MASLD/MASH & Cirrhosis

Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.

LiverMultiScan

Our cutting-edge, multiparametric MRI technology capabilities allow us to non-invasively characterize liver health by providing comprehensive measurements of liver fat, iron concentration, fibro-inflammation and more.

cT1 and MRI-PDFF have been shown to have high correlation with histological measures of fibrosis, inflammation, and steatosis. cT1 has been shown to reliably predict liver and cardiac clinical outcomes with an 80 ms change recognized as clinically significant.

Enhanced patient screening

Reduce screen fail rates, improve patient experience, and lower trial costs by pre-screening with our best-in-class imaging biomarkers before the initial biopsy.
‍
The histological features that contribute to steatohepatitis, including liver fat, fibrosis, and inflammation, can be characterized using MRI-PDFF and cT1.

Standardized and reproducible results

cT1 and MRI-PDFF have excellent reproducibility and repeatability with superior diagnostic accuracy. This enables reliable monitoring of disease progression and treatment response, allowing trials to be run with more confidence.
‍
Our proprietary technology corrects for iron content, field strength, and manufacturer differences to deliver a “corrected T1” or cT1, enabling and supporting large scale multi-site trials.

Digital pathology

"The workflow is the most intuitive and user-friendly system I’ve worked with"
‍
‍^{- Study pathologist in a phase 3 NASH study}

"We're happy with the service and the pathologists love the reporting system"
‍
‍^{- Medical Director phase 3 NASH trial}

Our pathology solution combines rapid, high-quality sample processing with a fully digitized reporting workflow and quantitative AI-pathology. It removes unnecessary shipping steps and enables multiple pathologists to report cases in parallel through a best-in-class digital viewing and eCRF-style reporting platforms.

Combined with industry-leading three-day sample processing, and fully automated report generation, our solution allows reports to be delivered to clinical sites in as little as 10 business days from receipt of tissue.

Quantifiable treatment response

AI-generated metrics provide a robust and reproducible method to quantify disease features. Gain insights into finer degrees of treatment response using our continuous AI-metrics:

% Steatosis
% Inflammatory burden and number of foci per mm²
Total number of ballooned hepatocytes and number of ballooned hepatocytes per mm²
% collagen proportionate area (CPA)

Esophagogastroduodenoscopy (EGD)

Our endoscopy central reading service supports both still images and HD videos. eCRF-style reporting templates, AI-enhanced quality checks and reads, and customizable consensus and adjudication workflows provide an enhanced reporting experience for central readers and reduce TATs.

HD recording equipment can be provided to sites to ensure standardized, high-quality data is collected in large-scale, multi-center studies.
‍

Back to focus areas

Autoimmune Disease

Accurate and precise non-invasive imaging biomarkers for characterizing and monitoring treatment response.

MRCP+

MRCP+ provides enhanced visualization and quantitative assessment of the biliary tree and pancreatic duct that cannot be obtained via a standard abdominal MRCP or ERCP. Enabling the evaluation hepatobiliary structures and accurate diagnosis, staging and monitoring of disease and treatment response.

The number of strictures measure provided by MRCP+ is the only biomarker under review by the FDA's Biomarker Qualification Program (BQP) for PSC

Combining MRCP+ with LiverMultiScan

cT1 provides a comprehensive whole liver slice assessment of fibro-inflammation, enabling non-invasive staging of disease activity and treatment response monitoring across several autoimmune liver conditions.

Case study

A 22-year old male with PSC/AIH overlap syndrome on prednisolone and azathioprine; responded to treatment

By combining LiverMultiScan with the quantitative measures provided by MRCP+, Perspectum enables precise monitoring of bile duct and parenchymal liver health across a range of autoimmune liver diseases in a single, non-contrast MRI scan.

Back to focus areas

Gastrointestinal Disease

We bring significant experience in streamlining and supporting large trials from Phase I to Phase III delivered through our in-house development workflow platform.

Quantifiable treatment response

Our AI-generated metrics provide a robust and reproducible method to quantify disease features. Gain insights into finer degrees of treatment response in ulcerative colitis using our continuous AI-metrics:

Density of lymphocytes and eosinophils
% inflammatory burden
% crypts with damage

Pathology Workflow

Customer Feedback

"The workflow is the most intuitive and user-friendly system I’ve worked with"
‍
‍^{- Study pathologist in a phase 3 NASH study}

"We're happy with the service and the pathologists love the reporting system"
‍
‍^{- Medical Director phase 3 NASH trial}

Endoscopy services and workflow

Our endoscopy central reading service supports both still images and HD videos. Our eCRF-style reporting templates, AI-enhanced quality checks, and customizable consensus and adjudication workflows enhance the reporting experience for central readers and reduce turnaround times. HD recording equipment can be provided to sites to ensure standardized, high-quality data is collected in large-scale, multi-center studies.

Back to focus areas

Oncology Solutions

Integrated analysis of our noninvasive, multi-organ & tumor characterization software, digital pathology, and endoscopy enables a deeper rapid analysis of the patient and their cancer

Advanced 3D medical imaging software

Revolutionizing oncology trials through expert central reads with improved standardization and reproducibility, and quantitative metrics of organ health and tumor burden. Allowing sponsors to better characterize disease burden and monitor tumor progression/response to treatment.

Recist
mRecist
Percist
Volume
Location
Activity

Enhanced screening and monitoring with cT1

By leveraging our proprietary MRI biomarker, cT1, sponsors can better identify patients for enrolment, more accurately detect early efficacy signals and pseudo-progression, and quantitatively monitor drug induced liver injury.

Custom imaging protocols and central reading workflows

Comprehensive support of advanced imaging capabilities

MRI
CT
PET
DXA
Endosocopy
Digital Pathology

Our customizable imaging protocol allows for non-invasive quantitative measures to be safely captured across many areas allowing Perspectum to deliver comprehensive solutions to meet your clinical trial needs. Natively supported areas are shown with further metrics available on request delivered through a globally scalable platform ensuring repeatable and reproducible measurements able to detect small change

Back to focus areas

Services

Digital Pathology

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam et dapibus odio. Duis et turpis rutrum, rhoncus eros ac, varius eros. Vestibulum magna ipsum, pharetra ac justo at, dictum euismod diam. Suspendisse lacinia erat a sapien dignissim, non efficitur eros.

Learn more